Researchers investigating sickle cell disease have profiled distinct gene expression patterns in erythroid cells, shedding new light on transcriptional alterations linked to hydroxyurea treatment. Sickle cell disease is an autosomal recessive monogenic condition defined by abnormal haemoglobin production and chronic haemolytic complications. Although hydroxyurea has long served as a standard first-line therapy for affected individuals, the full breadth of its biological mechanisms and its precise interactions with underlying disease pathways remain incompletely understood.
To investigate these molecular mechanisms, an investigative team led by researchers including Matthis Tinguely, Lennart Opitz, Markus Schmugge, and Francesca D. Franzoso examined transcriptional profiles across cultured red blood cell precursors. The investigators isolated peripheral blood mononuclear cells collected from patients diagnosed with sickle cell disease who were either actively undergoing treatment with hydroxyurea or remaining untreated. They subsequently compared these patient-derived cells against baseline samples gathered from healthy control individuals using bulk RNA sequencing techniques.
The sequencing analysis revealed substantial transcriptomic divergence between patient populations and the healthy control cohort. In erythroid cells differentiated from untreated sickle cell patients, the researchers identified 1,398 differentially expressed genes relative to healthy controls. By contrast, the erythroid cells derived from patients receiving hydroxyurea demonstrated a comparatively reduced set of transcriptional shifts, displaying 495 differentially expressed genes when measured against the same healthy baseline.
To interpret the physiological roles governed by these altered transcriptional signatures, the researchers conducted systematic functional enrichment analyses utilizing Gene Ontology classifications and Kyoto Encyclopedia of Genes and Genomes pathway mappings. This computational screening revealed significant alterations across several essential cellular programs, most notably oxidative phosphorylation cascades, proteasome activity, and autophagy regulation. The enrichment profiles also demonstrated notable involvement in immune-mediated networks, highlighting pathways associated with natural killer cell cytotoxicity, adaptive immune mechanisms, and broader inflammatory reactions.
To confirm the analytical accuracy of their sequencing data, the investigative team performed laboratory validation on a subset of the most prominent transcriptional signals. Using quantitative reverse transcription polymerase chain reaction assays, the authors validated 12 of the top differentially expressed genes identified in sickle cell disease samples in direct comparison with healthy control profiles, reinforcing the validity of the observed expression patterns across the cellular cohorts.
The study authors concluded that the identified genes and enriched molecular pathways could play fundamental roles in sickle cell disease pathogenesis. By pinpointing pathways spanning metabolic function, proteasomal regulation, and inflammatory signaling, the transcriptional profiles provide molecular candidates that may serve as targets for the future development of novel therapeutic strategies.
Methodologically, the experimental design centered on benchmarking differentiated cellular profiles against healthy controls rather than tracking individual patients over time. By using bulk RNA sequencing to examine cells from both untreated and treated cohorts, the researchers established distinct transcriptional snapshots. This framework illustrates how gene activity in sickle cell disease diverges from a healthy baseline.
These observations also define important boundaries for interpretation. Although identifying altered pathways in oxidative phosphorylation, proteasome function, and immune activity reveals key biological associations with disease pathogenesis, the authors presented these signatures as potential targets rather than proven therapies. Additional investigation remains necessary to determine how these mechanisms might guide future treatments.
Subject of Research: Transcriptomic profiling of hydroxyurea response and erythroid gene expression in sickle cell disease
Article Title: Transcriptomic signatures of hydroxyurea response in sickle cell disease
Article References: Tinguely, M., Opitz, L., Schmugge, M., & Franzoso, F. D. (2026). Transcriptomic signatures of hydroxyurea response in sickle cell disease. Human Genomics. https://doi.org/10.1186/s40246-026-01036-4
Image Credits: AI Generated
DOI: 10.1186/s40246-026-01036-4
Keywords: sickle cell disease, hydroxyurea, transcriptomics, RNA sequencing, erythroid cells, gene expression, differentially expressed genes, haemoglobin, haemolysis, quantitative RT-PCR, oxidative phosphorylation, proteasome, autophagy, natural killer cells, adaptive immune response, inflammation, functional enrichment, human genomics
Cite Scienmag News
Juliet Wilcox. (November 20, 2026). Sickle Cell Study Profiles Transcriptomic Shifts Linked to Hydroxyurea Therapy. Scienmag. https://scienmag.com/sickle-cell-study-profiles-transcriptomic-shifts-linked-to-hydroxyurea-therapy/
Juliet Wilcox. "Sickle Cell Study Profiles Transcriptomic Shifts Linked to Hydroxyurea Therapy." Scienmag, 20 November 2026, https://scienmag.com/sickle-cell-study-profiles-transcriptomic-shifts-linked-to-hydroxyurea-therapy/. Accessed 20 November 2026.
Juliet Wilcox. "Sickle Cell Study Profiles Transcriptomic Shifts Linked to Hydroxyurea Therapy." Scienmag. November 20, 2026. https://scienmag.com/sickle-cell-study-profiles-transcriptomic-shifts-linked-to-hydroxyurea-therapy/








